← Evidence map

ArticlePharmacoEconomics - open2026

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?

Iago Rodríguez-Lago et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? | OpenQuestion